Phase I, First in Human, Open Label Study to Evaluate Safety and Tolerability of TRX103 Cells in Subjects With Hematological Malignancies Undergoing HLA-mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TRX 103 (Primary)
Indications Graft-versus-host disease
Focus Adverse reactions; First in man; Proof of concept
Sponsors Tr1X

Most Recent Events

10 Jul 2024 According to Tr1X media release, first patient has been dosed in this trial. The first patient has successfully cleared the safety period with no serious adverse events. Additional preliminary safety and effectiveness data readouts expected by Q4 2024.
11 Jun 2024 Status changed from planning to recruiting.
10 Apr 2024 According to Tr1X media release, Monzr M. Al Malki, M.D., is the lead investigator of this Phase 1 study

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight